HRP20210418T1 - Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 - Google Patents
Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 Download PDFInfo
- Publication number
- HRP20210418T1 HRP20210418T1 HRP20210418TT HRP20210418T HRP20210418T1 HR P20210418 T1 HRP20210418 T1 HR P20210418T1 HR P20210418T T HRP20210418T T HR P20210418TT HR P20210418 T HRP20210418 T HR P20210418T HR P20210418 T1 HRP20210418 T1 HR P20210418T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- patient
- use according
- trastuzumab
- body weight
- Prior art date
Links
- 206010070308 Refractory cancer Diseases 0.000 title 1
- 208000016691 refractory malignant neoplasm Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 14
- 230000037396 body weight Effects 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 5
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 4
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 4
- 229960001612 trastuzumab emtansine Drugs 0.000 claims 4
- 238000001990 intravenous administration Methods 0.000 claims 3
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 229960000575 trastuzumab Drugs 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Spoj formule (I)
[image]
naznačen time što je namijenjen upotrebi u liječenju pacijenata s rakom pozitivnim na HER2 IHC 3+ ili HER2 IHC 2+/FISH, koji ne reagira na trastuzumab-emtanzin, gdje 2.6-2.9 predstavlja prosječni DAR za spoj.
2. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što je prosječni DAR za spoj otprilike 2.8.
3. Spoj namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što pacijent ne reagira ni na trastuzumab niti na trastuzumab-emtanzin.
4. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što pacijent ne reagira na sve od trastuzumaba, lapatiniba i trastuzumab-emtanzina.
5. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što je pacijent pacijent s rakom dojke.
6. Farmaceutski pripravak koji sadrži spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 5 i jedan ili više farmaceutskih prihvatljivih pomoćnih sredstava, naznačen time što je namijenjen upotrebi u liječenju pacijenata s rakom pozitivnim na HER2 IHC 3+ ili HER2 IHC 2+/FISH, koji ne reagira na trastuzumab-emtanzin.
7. Spoj ili farmaceutski pripravak namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačeni time što se pacijenta liječi, po mogućnosti svaka 3 tjedna, dozom u rasponu od otprilike 0.9 mg/kg do otprilike 2.1 mg/kg tjelesne težine pacijenta po intravenskoj primjeni, po mogućnosti od otprilike 1.2 do otprilike 1.8 mg/kg tjelesne težine pacijenta po intravenskoj primjeni.
8. Spoj ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 7, naznačeni time što je doza otprilike 0.9 mg/kg, otprilike 1.2 mg/kg, otprilike 1.5 mg/kg, otprilike 1.8 mg/kg, ili otprilike 2.1 mg/kg tjelesne težine pacijenta, po mogućnosti otprilike 1.2 mg/kg tjelesne težine pacijenta.
9. Spoj ili farmaceutski pripravak namijenjeni upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačen time što je prosječni DAR za spoj otprilike 2.8.
10. Spoj ili farmaceutski pripravak namijenjeni upotrebi u skladu s patentnim zahtjevom 1 ili 6, naznačeni time što je prosječni DAR za spoj otprilike 2.8, što je pacijent pacijent s rakom dojke, te što se pacijent liječi dozom od otprilike 1.2 mg/kg tjelesne težine pacijenta svaka 3 tjedna po intravenskoj primjeni.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15186258 | 2015-09-22 | ||
| EP16158710 | 2016-03-04 | ||
| EP16169699 | 2016-05-13 | ||
| PCT/EP2016/072464 WO2017050846A1 (en) | 2015-09-22 | 2016-09-21 | Syd985 treatment of t-dm1 refractory cancer patients |
| EP16775553.7A EP3352857B1 (en) | 2015-09-22 | 2016-09-21 | Syd985 treatment of t-dm1 refractory cancer patients |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210418T1 true HRP20210418T1 (hr) | 2021-04-30 |
Family
ID=57068063
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210418TT HRP20210418T1 (hr) | 2015-09-22 | 2021-03-12 | Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US10821191B2 (hr) |
| EP (1) | EP3352857B1 (hr) |
| JP (1) | JP6591665B2 (hr) |
| KR (1) | KR20180052761A (hr) |
| CN (1) | CN108025190A (hr) |
| AU (1) | AU2016328461B2 (hr) |
| BR (1) | BR112018005494A2 (hr) |
| CA (1) | CA2996600A1 (hr) |
| CL (1) | CL2018000726A1 (hr) |
| CY (1) | CY1123818T1 (hr) |
| DK (1) | DK3352857T3 (hr) |
| ES (1) | ES2854298T3 (hr) |
| HR (1) | HRP20210418T1 (hr) |
| HU (1) | HUE053614T2 (hr) |
| LT (1) | LT3352857T (hr) |
| MX (1) | MX2018003459A (hr) |
| MY (1) | MY194488A (hr) |
| PL (1) | PL3352857T3 (hr) |
| RU (1) | RU2728101C2 (hr) |
| WO (1) | WO2017050846A1 (hr) |
| ZA (1) | ZA201801022B (hr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021005484A (es) * | 2018-11-09 | 2021-06-18 | Byondis Bv | Composiciones de conjugados de anticuerpo-farmaco que contienen duocarmicina filtrable y metodos relacionados. |
| MX2022007721A (es) * | 2019-12-20 | 2022-07-19 | Pfizer | Tratamiento con conjugados de farmaco-anticuerpo her2 especifico del sitio. |
| CN118159293A (zh) * | 2021-10-20 | 2024-06-07 | 国立研究开发法人产业技术综合研究所 | 抗癌药、抗癌药的前药、在体外杀灭癌细胞的方法、癌症的治疗方法、以及癌症的治疗装置 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009052249A1 (en) * | 2007-10-19 | 2009-04-23 | Genentech, Inc. | Cysteine engineered anti-tenb2 antibodies and antibody drug conjugates |
| HUE030846T2 (en) * | 2010-04-21 | 2017-06-28 | Syntarga Bv | Conjugates of CC-1065 analogues and bifunctional linkers |
| CA2935433C (en) | 2014-01-10 | 2019-04-02 | Synthon Biopharmaceuticals B.V. | Duocarmycin anti-her2 antibody drug conjucates with activity against her2 expressing malignancies |
-
2016
- 2016-09-21 BR BR112018005494A patent/BR112018005494A2/pt not_active Application Discontinuation
- 2016-09-21 EP EP16775553.7A patent/EP3352857B1/en active Active
- 2016-09-21 HU HUE16775553A patent/HUE053614T2/hu unknown
- 2016-09-21 KR KR1020187010953A patent/KR20180052761A/ko unknown
- 2016-09-21 RU RU2018114457A patent/RU2728101C2/ru active
- 2016-09-21 JP JP2018515142A patent/JP6591665B2/ja active Active
- 2016-09-21 ES ES16775553T patent/ES2854298T3/es active Active
- 2016-09-21 CN CN201680054664.3A patent/CN108025190A/zh active Pending
- 2016-09-21 MY MYPI2018000414A patent/MY194488A/en unknown
- 2016-09-21 AU AU2016328461A patent/AU2016328461B2/en active Active
- 2016-09-21 WO PCT/EP2016/072464 patent/WO2017050846A1/en active Application Filing
- 2016-09-21 DK DK16775553.7T patent/DK3352857T3/da active
- 2016-09-21 US US15/762,171 patent/US10821191B2/en active Active
- 2016-09-21 MX MX2018003459A patent/MX2018003459A/es unknown
- 2016-09-21 PL PL16775553T patent/PL3352857T3/pl unknown
- 2016-09-21 LT LTEP16775553.7T patent/LT3352857T/lt unknown
- 2016-09-21 CA CA2996600A patent/CA2996600A1/en active Pending
-
2018
- 2018-02-14 ZA ZA2018/01022A patent/ZA201801022B/en unknown
- 2018-03-20 CL CL2018000726A patent/CL2018000726A1/es unknown
-
2021
- 2021-02-16 CY CY20211100128T patent/CY1123818T1/el unknown
- 2021-03-12 HR HRP20210418TT patent/HRP20210418T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| LT3352857T (lt) | 2021-02-25 |
| ES2854298T3 (es) | 2021-09-21 |
| JP6591665B2 (ja) | 2019-10-16 |
| PL3352857T3 (pl) | 2021-08-02 |
| CY1123818T1 (el) | 2022-05-27 |
| HUE053614T2 (hu) | 2021-07-28 |
| RU2018114457A (ru) | 2019-10-24 |
| AU2016328461A1 (en) | 2018-02-22 |
| WO2017050846A1 (en) | 2017-03-30 |
| BR112018005494A2 (pt) | 2018-10-09 |
| RU2018114457A3 (hr) | 2020-01-31 |
| RU2728101C2 (ru) | 2020-07-28 |
| CA2996600A1 (en) | 2017-03-30 |
| EP3352857B1 (en) | 2021-01-13 |
| EP3352857A1 (en) | 2018-08-01 |
| US10821191B2 (en) | 2020-11-03 |
| US20180280533A1 (en) | 2018-10-04 |
| DK3352857T3 (da) | 2021-03-01 |
| AU2016328461B2 (en) | 2021-04-08 |
| CL2018000726A1 (es) | 2018-06-01 |
| CN108025190A (zh) | 2018-05-11 |
| MY194488A (en) | 2022-11-30 |
| JP2018527402A (ja) | 2018-09-20 |
| KR20180052761A (ko) | 2018-05-18 |
| MX2018003459A (es) | 2018-06-06 |
| ZA201801022B (en) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210418T1 (hr) | Liječenje s syd985 pacijenata s rakom koji ne reagira na t-dm1 | |
| HRP20200991T1 (hr) | Modulator androgenog receptora u kombinaciji s abirateron acetatom i prednizonom za liječenje karcinoma prostate | |
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| RU2013156378A (ru) | 4-амино-5-фтор-3-[6-(4-метилпиперазин-1-ил)-1н-бензимидазол-2-ил]-1н-хинолин-2-он для применения при лечении аденокистозной карциномы | |
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| RU2010140682A (ru) | Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство | |
| JP2017506624A5 (hr) | ||
| JP2018184465A5 (hr) | ||
| NZ600544A (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| MX2016011333A (es) | Sistemas de administracion de farmaco y metodo para el tratamiento de cancer de vejiga con gemcitabina. | |
| HRP20180071T4 (hr) | Upotreba kladribina u liječenju očnog neuromijelitisa | |
| MX2017003780A (es) | Composicion farmaceutica para tratar colitis ulcerativa. | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| HRP20210010T1 (hr) | Injekcijske farmaceutske formulacije lefamulina | |
| RU2019134416A (ru) | Фармацевтические композиции | |
| JP2015522033A5 (hr) | ||
| JP2014148552A5 (hr) | ||
| JP2016505050A5 (hr) | ||
| JP2020531568A5 (hr) | ||
| MX2019008482A (es) | Tratamiento medico que comprende administracion enteral de edaravona. | |
| JP2019535830A5 (hr) | ||
| NZ703729A (en) | Combinations with a backbone-cyclized peptide | |
| RU2015111491A (ru) | Комбинация макроциклического ингибитора протеазы hcv, ненуклеозидного ингибитора hcv и ритонавира | |
| RU2014128528A (ru) | Лечение диабета I и II типа | |
| FI3654989T3 (fi) | Kladribiinin käyttö neuromuskulaarisen autoimmuunisairauden hoitoon |